Collectively, these data suggest that chronic treatment of hG6PC S298C mRNA reduces the risk of HCA/HCC, a long-term complication with GSD1a by functional restoration of hepatic G6Pase. The gene discussed is G6PC1; the disease is hepatocellular adenoma.